Aminoglycoside-induced hearing loss in HIV-positive and HIV-negtive multidrug-resistant tuberculosis patients
dc.contributor.author | Harris, Tashneem | |
dc.contributor.author | Bardien, Soraya | |
dc.contributor.author | Schaaf, H. Simon | |
dc.contributor.author | Petersen, Lucretia | |
dc.contributor.author | De Jong, Greetje | |
dc.contributor.author | Fagan, Johannes J. | |
dc.date.accessioned | 2013-07-03T08:19:09Z | |
dc.date.available | 2013-07-03T08:19:09Z | |
dc.date.issued | 2012-06 | |
dc.description | The original publication is available at http://www.samj.org.za | en_ZA |
dc.description.abstract | Background. Ototoxicity following aminoglycoside treatment for multidrug-resistant tuberculosis (MDR-TB), is a significant problem. This study documents the incidence of ototoxicity in HIVpositive and HIV-negative patients with MDR-TB and presents clinical guidelines relating to ototoxicity. Methods. A prospective cohort study of 153 MDR-TB patients with normal hearing and middle ear status at baseline controlling for 6 mitochondrial mutations associated with aminoglycosiderelated ototoxicity, at Brooklyn Chest Hospital in Cape Town. Pure tone audiometry was performed monthly for 3 months to determine hearing loss. HIV status was recorded, as was the presence of 6 mutations in the MT-RNR1 gene. Results. Fifty-seven per cent developed high-frequency hearing loss. HIV-positive patients (70%) were more likely to develop hearing loss than HIV-negative patients (42%). Of 115 patients who were genetically screened, none had MT-RNR1 mutations. Conclusion. Ototoxic hearing loss is common in MDR-TB patients treated with aminoglycosides. HIV-positive patients are at increased risk of ototoxicity. Auditory monitoring and auditory rehabilitation should be an integral part of the package of care of MDR-TB patients. | en_ZA |
dc.description.sponsorship | Medical Research Council | en_ZA |
dc.description.sponsorship | Stellenbosch University | en_ZA |
dc.description.sponsorship | South African Society of Otorhinolarynogology | |
dc.format.extent | pp. 363-365 | |
dc.identifier.citation | Harris, T. et al. 2012. Aminoglycoside-induced hearing loss in HIV-positive and HIV-negtive multidrug-resistant tuberculosis patients. South African Medical Journal102(6):363-366. | en_ZA |
dc.identifier.issn | 2078-5135 (online) | |
dc.identifier.issn | 0256-9574 (print) | |
dc.identifier.uri | http://hdl.handle.net/10019.1/81850 | |
dc.language.iso | en_ZA | |
dc.publisher | Health and Medical Publishing Group (HMPG) | |
dc.rights.holder | Authors retain copyright | en_ZA |
dc.subject | Ototoxic agents | en_ZA |
dc.subject | Aminoglycosides induced ototoxicity | en_ZA |
dc.subject | Drug resistant tuberculosis patients -- Loss of hearing | en_ZA |
dc.subject | HIV positive patients and loss of hearing | en_ZA |
dc.title | Aminoglycoside-induced hearing loss in HIV-positive and HIV-negtive multidrug-resistant tuberculosis patients | en_ZA |
dc.type | Article | en_ZA |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- harris_aminoglycoside_2012.pdf
- Size:
- 538.04 KB
- Format:
- Adobe Portable Document Format
- Description:
- Publishers' Version